Breaking News, Trials & Filings

UCB Wins FDA Approval of ZILBRYSQ to Treat Myasthenia Gravis

Becomes the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

UCB, a global biopharmaceutical company, received approval from the FDA for ZILBRYSQ (zilucoplan) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.   ZILBRYSQ is the first once-daily subcutaneous, targeted peptide inhibitor of complement component 5 (C5 inhibitor)2. It is the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.   As a complement...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters